| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Mogamulizumab manufacturers
- Mogamulizumab
-
- $243.00
-
2026-07-27
- CAS:1159266-37-1
- Purity: 99.4% (SEC-HPLC)
- Supply Ability: 10g
|
| | Mogamulizumab Basic information |
| Product Name: | Mogamulizumab | | Synonyms: | Mogamulizumab;Research Grade Mogamulizumab (DHE85301);Mogamulizumab (anti-CCR4);KW-0761;Research Grade Mogamulizumab | | CAS: | 1159266-37-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Mogamulizumab Structure]() |
| | Mogamulizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Mogamulizumab Usage And Synthesis |
| Uses | Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3]. | | in vivo | Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model[2].
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs[4].
| Animal Model: | Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)[2] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks. | | Result: | Suppressed Tumor growth with vacuolar degeneration. |
| | IC 50 | CCR4 | | References | [1] Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7(3):171-4. DOI:10.1177/2040620716636541
[2] Kanazawa T, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014 Oct 1;20(19):5075-84. DOI:10.1158/1078-0432.CCR-14-0580
[3] Yamauchi J, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 Jan 15;211(2):238-48. DOI:10.1093/infdis/jiu438
[4] Maeda S, et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunol Res. 2019 Jul;7(7):1175-1187. DOI:10.1158/2326-6066.CIR-18-0751 |
| | Mogamulizumab Preparation Products And Raw materials |
|